The United States saw a dramatic increase in fireworks-related deaths and injuries last year. Here's how to stay safe.

AstraZeneca PLC (NASDAQ:AZN) is one of the 11 Best Strong Buy Stocks to Invest in Now. On June 13, AstraZeneca PLC ...

AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs.

CSPC has a very strong financial position. As of 2022, its total debt outstanding is only 1.8% of its total cash in hand. Its annual capital expenditure for 2022 was CNY 1.8 billion.

AstraZeneca said it entered into a strategic research collaboration with China’s CSPC Pharmaceuticals, focused on artificial intelligence-driven research, valued at up to $5.33 billion.

On June 13, 2025, AstraZeneca announced a strategic research collaboration with CSPC Pharmaceuticals to advance AI-enabled drug discovery. This partnership aims to develop novel oral candidates ...

CSPC Pharma pocketed $150 million upfront and retains the right to up to $135 million in staged development payments and up to $1.55 billion in fees related to sales milestones.

CSPC Pharmaceutical Group, with a market cap of HK$50.61 billion, has been actively expanding its R&D efforts despite recent revenue challenges due to declining caffeine prices and health food sales.

AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug. The deal, which covers a potential rival to an Eli Lilly prospect, positions AstraZeneca ...